Results 21 to 30 of about 3,283 (198)

Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema [PDF]

Clinical Ophthalmology
Purpose The purpose of this study was to assess preliminary real-world outcomes in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) treated with intravitreal faricimab.
Nicole Q X Quah, K. M. A. A. Javed, Lamees Arbi, Daren Hanumunthadu   +3 more
semanticscholar   +2 more sources

Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration [PDF]

Clinical Ophthalmology
Abraham Hang, Taylor Ngo, Jaipreet Singh Virk, Kareem Moussa, Ala Moshiri, Parisa Emami-Naeini, Susanna S Park Department of Ophthalmology & Vision Science, University of California Davis Eye Center, Sacramento, CA, USACorrespondence: Susanna S Park ...
Hang A, Ngo T, Virk JS, Moussa K, Moshiri A, Emami-Naeini P, Park SS   +6 more
doaj   +4 more sources

Occlusive retinal vasculitis associated with intravitreal Faricimab injections [PDF]

Journal of Ophthalmic Inflammation and Infection
Purpose We describe a case of occlusive vasculitis associated with intravitreal Faricimab (Vabysmo) injections. Methods A retrospective case report. Results A 52-year old man treated with monthly Faricimab injections for diabetic macula oedema presented ...
Felix F. Reichel, Peter Kiraly, Roopa Vemala, Stella Hornby, Samantha R. De Silva, M. Dominik Fischer   +5 more
doaj   +2 more sources

Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review [PDF]

International Journal of Retina and Vitreous
Background To systematically review the real-world outcomes of intravitreal faricimab treatment in patients with neovascular age-related macular degeneration (nAMD) to evaluate its efficacy and safety in clinical settings. This study was conducted due to
Nasratullah Nasimi, Safiullah Nasimi, Jakob Grauslund, Anna Stage Vergmann, Yousif Subhi   +4 more
doaj   +2 more sources

Sterile Intraocular Inflammation Associated With Faricimab

JAMA ophthalmology
This case series study evaluates the characteristics and outcomes of sterile intraocular inflammation after injection of faricimab to treat neovascular age-related macular degeneration or diabetic macular edema.
Mariano Cozzi, A. Ziegler, Katrin Fasler, D. Muth, F. Blaser, S. Zweifel   +5 more
semanticscholar   +2 more sources

A case of hypertensive uveitis with intravitreal faricimab

, 2023
PURPOSE: To report a novel case of hypertensive uveitis with intravitreal faricimab. METHODS: This is a case report. A 69-year-old female undergoing treatment of bilateral diabetic macular oedema with intravitreal faricimab presented for routine review ...
McAllister, Andrew, Kitson, Samantha
core   +1 more source

Faricimab: First Approval

, 2022
Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the ...
Matt Shirley (7340599)
core   +1 more source

Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration [PDF]

, 2023
Nowadays; intravitreal anti-vascular endothelial growth factor (VEGF) drugs are considered the first-line therapeutic strategy for treating macular exudative diseases; including wet age-related macular degeneration (w-AMD) and diabetic macular edema (DME)
Nicolò, Massimo, Carlo Enrico Traverso, Ferro Desideri, Lorenzo, Massimo Nicolò, Lorenzo Ferro Desideri, Marion R. Munk, Traverso, Carlo Enrico, Munk, Marion R   +7 more
core   +2 more sources

Faricimab for treating diabetic macular oedema

, 2021
To appraise the clinical and cost effectiveness of faricimab within its marketing authorisation for treating diabetic macular ...
Frampton, Geoff, Scott, David Alexander, Kalita, Neelam, Maund, Emma, Cooper, Keith, Pickett, Karen, Takahashi, Marcia Tomie   +6 more
core   +1 more source

TENAYA and LUCERNE: 2-Year Results from the Phase 3 nAMD Trials of Faricimab with Treat-and-Extend Dosing in Year 2.

Ophthalmology (Rochester, Minn.)
PURPOSE To evaluate the 2-year efficacy, durability, and safety of the bispecific antibody, faricimab, which inhibits both angiopoietin-2 and vascular endothelial growth factor-A.
A. Khanani, A. Kotecha, Andrew Chang, Shih-Jen Chen, You-Xin Chen, Robyn Guymer, Jeffrey S. Heier, F. Holz, Tomohiro Iida, Jane A. Ives, Jennifer I. Lim, Hugh Lin, Stephan Michels, Carlos Quezada Ruiz, Ursula Schmidt-Erfurth, David Silverman, Rishi P. Singh, Balakumar Swaminathan, Jeffrey R. Willis, R. Tadayoni   +19 more
semanticscholar   +1 more source